New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Last Close
Oct 10  •  04:00PM ET
15.54
Dollar change
-0.16
Percentage change
-1.02
%
Index- P/E- EPS (ttm)-4.76 Insider Own10.36% Shs Outstand12.25M Perf Week4.79%
Market Cap190.45M Forward P/E- EPS next Y-5.26 Insider Trans-0.33% Shs Float10.99M Perf Month63.58%
Enterprise Value76.03M PEG- EPS next Q-1.71 Inst Own65.16% Short Float10.66% Perf Quarter85.89%
Income-57.95M P/S- EPS this Y-74.51% Inst Trans-9.56% Short Ratio8.76 Perf Half Y173.11%
Sales0.00M P/B1.72 EPS next Y18.08% ROA-41.83% Short Interest1.17M Perf YTD31.69%
Book/sh9.06 P/C1.63 EPS next 5Y-18.63% ROE-49.00% 52W High20.77 -25.18% Perf Year-20.63%
Cash/sh9.54 P/FCF- EPS past 3/5Y30.83% 35.71% ROIC-51.86% 52W Low4.64 234.91% Perf 3Y207.24%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility9.05% 8.20% Perf 5Y-72.59%
Dividend TTM- EV/Sales- EPS Y/Y TTM18.15% Oper. Margin- ATR (14)0.96 Perf 10Y-68.22%
Dividend Ex-Date- Quick Ratio9.21 Sales Y/Y TTM- Profit Margin- RSI (14)73.54 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio9.21 EPS Q/Q-59.54% SMA2022.93% Beta2.70 Target Price38.80
Payout- Debt/Eq0.02 Sales Q/Q- SMA5044.61% Rel Volume2.97 Prev Close15.70
Employees28 LT Debt/Eq0.01 EarningsAug 05 BMO SMA20074.65% Avg Volume133.80K Price15.54
IPOOct 27, 2014 Option/ShortYes / Yes EPS/Sales Surpr.3.72% - Trades Volume397,590 Change-1.02%
Date Action Analyst Rating Change Price Target Change
Jul-30-25Resumed B. Riley Securities Buy $28
Feb-28-25Initiated William Blair Outperform
Dec-02-24Initiated Piper Sandler Overweight
Jul-30-24Initiated Wedbush Outperform $85
Jul-22-24Resumed H.C. Wainwright Buy $80
Jun-26-24Initiated B. Riley Securities Buy $85
Jun-03-24Reiterated Oppenheimer Outperform $60 → $80
May-13-24Initiated RBC Capital Mkts Outperform $77
Mar-06-24Upgrade Jefferies Hold → Buy $4 → $46
Sep-08-20Downgrade ROTH Capital Buy → Neutral $40 → $3
Oct-07-25 08:00AM
Sep-22-25 08:00AM
Sep-16-25 08:00AM
Aug-08-25 10:15AM
Aug-05-25 08:11AM
08:00AM Loading…
08:00AM
Jul-30-25 08:00AM
Jun-30-25 08:00AM
Jun-25-25 08:00AM
Jun-24-25 04:05PM
May-23-25 11:13AM
May-22-25 08:00AM
May-19-25 08:00AM
May-16-25 07:48AM
May-08-25 08:00AM
07:20AM Loading…
07:20AM
May-06-25 08:08AM
08:00AM
Apr-29-25 08:14AM
Apr-18-25 09:55AM
Mar-28-25 08:00AM
Mar-20-25 09:35AM
Mar-19-25 09:35AM
Mar-13-25 12:00PM
Mar-11-25 08:17AM
08:00AM
Feb-25-25 08:00AM
Feb-14-25 01:17PM
07:30AM
Feb-11-25 07:30AM
08:00AM Loading…
Jan-28-25 08:00AM
Jan-08-25 08:00AM
Jan-06-25 08:00AM
Dec-09-24 07:00AM
Dec-04-24 12:31PM
Dec-03-24 07:00AM
Nov-26-24 06:54AM
Nov-21-24 08:00AM
Nov-12-24 08:00AM
Nov-07-24 07:28AM
07:00AM
Nov-04-24 04:10PM
07:00AM
Oct-29-24 08:00AM
Oct-16-24 08:00AM
Oct-15-24 07:02PM
Oct-11-24 07:02PM
Oct-03-24 05:07AM
Sep-26-24 08:00AM
Sep-24-24 09:41PM
Sep-20-24 03:18PM
Sep-12-24 07:59AM
Sep-05-24 08:00AM
Sep-04-24 07:29PM
Sep-02-24 05:22PM
Aug-27-24 08:03PM
Aug-26-24 09:55AM
Aug-21-24 05:00AM
Aug-20-24 08:00AM
Aug-09-24 12:00PM
09:55AM
Aug-06-24 08:08AM
08:00AM
Jul-30-24 08:50AM
Jul-01-24 11:13AM
Jun-30-24 10:13AM
Jun-01-24 10:00AM
May-30-24 08:00AM
May-23-24 05:05PM
May-17-24 04:12PM
May-09-24 08:00AM
May-07-24 01:52PM
08:17AM
08:00AM
May-06-24 02:06PM
May-01-24 08:00AM
Apr-24-24 04:05PM
Apr-19-24 02:30PM
Apr-16-24 08:50AM
Apr-12-24 06:40AM
Apr-02-24 08:00AM
Mar-15-24 08:50AM
Mar-14-24 09:38AM
Mar-12-24 08:21AM
08:00AM
Mar-06-24 08:00AM
Feb-28-24 08:00AM
Feb-06-24 09:50AM
Feb-02-24 04:01PM
Jan-31-24 09:19AM
Jan-30-24 06:55PM
Jan-29-24 06:57AM
Jan-26-24 07:30AM
Jan-23-24 08:00AM
Jan-09-24 08:00AM
Dec-18-23 08:00AM
Dec-01-23 09:40AM
Nov-07-23 09:56AM
08:11AM
08:00AM
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jenkins John KennethDirectorMay 30 '25Sale7.352,78320,46533Jun 02 04:30 PM
Altmeyer AnneDirectorMay 30 '25Sale7.251,39210,0961,391Jun 02 04:30 PM
Smethurst DominicChief Medical OfficerMar 06 '25Sale6.786,39343,33070,807Mar 07 04:30 PM
Smethurst DominicOfficerMar 06 '25Proposed Sale6.846,39343,728Mar 06 04:03 PM
Moran Sean F.Chief Financial OfficerFeb 14 '25Sale8.762,79224,44673,313Feb 18 05:40 PM
Cohen YuvalChief Executive OfficerFeb 14 '25Sale8.767,13462,465138,187Feb 18 05:40 PM
Moran Sean F.OfficerFeb 14 '25Proposed Sale9.482,79226,468Feb 14 04:18 PM
Cohen YuvalOfficerFeb 14 '25Proposed Sale9.487,13467,630Feb 14 04:16 PM